Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies

SARS-CoV-2, the autoimmune virus

Diverse Functional Autoantibodies in Patients with COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

More than a year after COVID-19 emerged, many mysteries persist about the disease: why do some people get so much sicker than others? Why does lung damage sometimes continue to worsen well after the body seems to have cleared the SARS-CoV-2 virus? And what is behind the extended, multi-organ illness that lasts for months in people with ‘long COVID’? A growing number of studies suggest that some of these questions might be explained by the immune system mistakenly turning against the body — a phenomenon known as autoimmunity.

Systemic lupus erythematosus (SLE), the embodiment of a multi-organ autoimmune disease, results from hyperactivation of host-defence pathways and immune recognition of the most fundamental building blocks of life. In 2018, key advances have placed intestinal immunity and dysregulated expansions of candidate pathobionts at the forefront of SLE pathogenesis.

The Microbiome and Systemic Lupus Erythematosus

Systemic Lupus Erythematosus and dysbiosis in the microbiome: cause or effect or both?

Response to: ‘The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus’ by Zhang et al and the phylogeny of a candidate pathobiont in lupus nephritis

Is Gut Microbial LPS a Potential Trigger of Juvenile Idiopathic Arthritis?